Trial Profile
A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Isoniazid (Primary) ; Ethambutol; Pyrazinamide; Rifampicin
- Indications Liver injury; Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Orient Pharma
- 14 Jun 2022 Status changed from suspended to completed.
- 03 May 2021 Planned End Date changed from 1 Dec 2017 to 1 Dec 2022.
- 03 May 2021 Status changed from recruiting to suspended.